Will men attribute fault to their GP for adverse effects arising from controversial screening tests? An Australian study using scenarios about PSA screening

Journal of Medical Screening

Volumn 11, Issue 4, 2004, Pages 165-169

  Gattellari, Melina ^a   Ward, Jeanette E ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ATTITUDE; AUSTRALIA; CANCER SCREENING; CLINICAL PRACTICE; CONFIDENCE INTERVAL; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EVALUATION; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEALTH STATUS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT EDUCATION; POPULATION RESEARCH; PREDICTION; PROSTATE CANCER; RESPONSIBILITY; SCORING SYSTEM; SCREENING TEST;

AGED; AUSTRALIA; DEMOGRAPHY; FAMILY PRACTICE; HEALTH STATUS; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SOCIOECONOMIC FACTORS;

EID: 10844248374     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1258/0969141042467386     Document Type: Article

References (36)

1. Scharwtz LM, Woloshin S, Fowler FJ, Welch FJ, Welch HG. Enthusiasm for screening in the United States. JAMA 2004;291:71-78.
2. Meyer F, Moore L, Bairati I, Fradet Y. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 1999;161:1189-91.
3. Smith DP, Armstrong BK. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. Med J Austr 1998;169:17-20.
4. Pinnock CB, Weller DP, Marshall VR (1998). Self-reported prevalence of prostate-specific antigen testing in South Australia. Med J Austr 1998;169:25-28.
5. Perkins JJ, Sanson-Fisher RW, Clarke SJ, Youman P. An exploration of screening practices for prostate cancer and the associated screening expenditure. Br J Urol 1998;82:524-29.
6. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:917-29.
7. de Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE. ERSPC. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial, Int J Cancer 2002;98:26B-73.
8. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21:273S-309S.
9. National Cancer Institute. Prostate Cancer Screening and Testing. http://www.nci.nih.gov/cancer_information/testing/.
10. Feightner JW. Screening for prostate cancer. In: The Canadian guide to clinical preventive health care, Canadian Task Force on Preventive Health Care. http://www.ctfphc.org/.
11. Canadian Cancer Society. Canadian Cancer Society perspective on early detection and treatment of prostate cancer http://www.cancer.ca/ccs/internet/ standard/0,3182,3172_428338_4 28444_langld-en,00.html. Last accessed December 31, 2003.
12. National Health Service. Prostate Cancer Risk Management Prostate Cancer Risk Management. http://www.cancerscreening.nhs.uk/prostate/index.html.
13. Advisory committee on cancer prevention. Position paper: recommendations on cancer screening in the European Union. Eur J Cancer 2000;36:1473-78.
14. The Cancer Council Australia. National Cancer Prevention Policy 2001-03. Sydney: The Cancer Council Australia, 2001.
15. Slevin TJ, Donnelly N, Clarkson JP, English DR, Ward JE. Prostate cancer testing: behaviour, motivation and attitudes among Western Australian men. Med J Austr 1999;171:185-88.
16. Dunn AS, Shridharai KV, Lou W, Bernstein J, Horowitz CR. Physician-patient discussions of controversial cancer screening tests. Am J Prevent Med 2001;20:130-34.
17. Ransohoff DF, McNaughton Collins M, Fowler FJ. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 2002;113:663-67.
18. Girgis S, Ward JE, Thomson CJH. General practitioners' perceptions of medicolegal risk. Med J Austr 1999;171:362-66.
19. Austin OJ, Valente S, Hasse LA, Kues JR. Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians. Arch Fam Med 1997;6:453-58.
20. Gattellari M, Ward JE. A community-based randomised controlled trial of three different educational resources for men about prostate cancer screening. Patient Education and Counseling (in press).
21. Hosmer DW, Lemeshow S. Applied logistic regression. Brisbane: John Wiley and Sons, 2001.
22. Norusis JM/SPSS Inc. SPSS for Windows-based system user's guide release 12.0. Chicago; SPSS Inc: 2003.
23. Fleiss JL. Statistical methods for rates and proportions. New York: Wiley, 1981.
24. Public Health Division. The health of the people of New South Wales-report of the Chief Health Officer, 2002. Sydney: NSW Department of Health, 2002.
25. Australian Bureau of Statistics (ABS). Australian Standard Classifications of Occupations 2nd Edition Canberra: AGPS, 1997.
26. Ware J. MOS SF36 Health survey: Manual and interpretation guide. Boston: The Health Institute, 1993.
27. Degner LF, Sloan JA, Venkatesh P. The control preferences scale. Can J Nurs Res 1997;29:21-43.
28. Lau RR. Origins of health locus of control beliefs. J Personal Soc Psychol 1982;42:322-34.
29. Marshall GN, Collins BE, Crooks VC. A comparison of two multidimensional health locus of control instruments. J Personal Assess 1990;54:181-90.
30. O'Connor AM. Validation of decisional conflict scale. Med Decision Making 1995;15:25-30.
31. Gattellari M, Ward J. Does evidence-based information about prostate cancer screening enhance consumer decision-making? A randomised controlled trial. J Med Screen 2003;10:27-39.
32. Redelmeier DA, Rozin P, Kahneman D. Understanding patients' decisions cognitive and emotional perspectives. J Am Med Assoc 1993;270:72-76.
33. Phillips RL Jr, Bartholomew LA, Dovey SM, Fryer GE Jr, Miyoshi TJ, Green LA. Learning from malpractice claims about negligent, adverse events in primary care in the United States. Qual Safe Health Care 2004;13:121-26.
34. Pinnock CB. PSA testing in general practice: can we do more now? Med J Austr 2004;180:379-81.
35. O'Connor AM, Rostom A, Fiset V, et al. Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ 1999;319:731-34.
36. Farrell MH, Murphy MA, Schneider CE. How underlying physician beliefs can affect physician-patient communication about prostate-specific antigen testing. Effect Clin Pract 2002;5:120-29.